Glucagon-like peptide-1 receptor agonists tied to higher thyroid cancer risk in first year of treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...
Renal & Urology News2d
GLP-1 Receptor Agonists May Have Broader Range of Benefits, Risks
With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...
thecardiologyadvisor.com2d
GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss
For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.
Nature8d
Glucagon-Like Peptide-1 Receptor Agonists and Their Effects on Appetite and Behavior
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily used to treat Type 2 diabetes and obesity. Recent research has expanded their potential applications ...
HealthDay on MSN9d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
WEDNESDAY, Jan. 22, 2025 (HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an ...
BMJ2d
GLP-1 agonists may raise risk of pulmonary aspiration during surgery, MHRA warns
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...
Endocrinology Advisor3d
Select GLP-1 Receptor Agonists Reduce Risk of CKD Progression, ESKD, and MACE
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...
EurekAlert!1d
Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among us adults with overweight or obesity
In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within 1 year, but those without type 2 diabetes had higher ...
emjreviews.com4d
GLP-1 Receptor Agonists Linked to Behavioural Side Effects
A RECENT population-based analysis has highlighted potential behavioural side effects associated with Glucagon-like peptide 1 ...
Medical News Today11d
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
Renal & Urology News5d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
Authors say large, multisite study should provide reassurance for short-term risk. (HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased ...
Monthly Prescribing Reference9d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3 years. HealthDay News — Glucagon-like peptide 1 receptor ...